妊娠及产后皮肤病发作的管理:第二部分——管理与安全性考量
本文为继续医学教育第二部分,针对妊娠及哺乳期常见的特应性皮炎、银屑病、痤疮、玫瑰痤疮、黄褐斑、脱发及化脓性汗腺炎等皮肤病,整合最新安全性数据、孕期剂量调整、哺乳期药理学及临床算法,旨在优化母体疾病控制并降低胎儿及新生儿风险。文中指出当前治疗信息分散,仅依赖FDA妊娠分类和个案经验导致实践差异大、有效治疗常被 withheld。
要点
- 妊娠哺乳期皮肤病治疗需整合安全性数据与孕期剂量调整,避免治疗不足。
- 不应仅依赖FDA妊娠分类和个案经验,应参考最新证据框架。
- 哺乳期用药需结合药理学知识,提供一致哺乳指导。
核心结论
- 针对妊娠及产后发作的多种皮肤病,需采用整合安全性、剂量调整和哺乳药理学的循证框架来优化管理。
研究设计与样本
- 本文为继续医学教育(CME)第二部分,基于文献与注册报告汇总证据,未报告系统检索范围或样本量。
主要发现
- 多种外用、系统及操作治疗(包括新型生物制剂、小分子免疫调节剂和窄谱UVB)已显示疗效,但安全性和剂量数据分散于不同专业文献和注册报告。
- 仅依赖FDA妊娠分类和个案经验导致实践差异大、治疗缺口,有效治疗常被 withheld、亚治疗剂量方案被处方、哺乳指导不一致。
- 孕妇和哺乳期女性被排除在随机试验外,关键药代动力学和致畸性问题未解答。
关键数值与推荐
- 文中提出针对特应性皮炎、银屑病、痤疮、玫瑰痤疮、黄褐斑、脱发(休止期脱发或雄激素性、激素和/或营养相关)及化脓性汗腺炎的整合框架,包含最新安全性特征、孕期剂量调整、哺乳期药理学和临床算法。
临床怎么用
- 临床应使用整合框架管理妊娠哺乳期皮肤病,避免治疗不足,并基于最新证据进行孕期剂量调整和哺乳指导。
局限性
- 孕妇和哺乳期女性被排除在随机试验外,关键药代动力学和致畸性问题未解答。
- 安全性和剂量数据分散于不同专业文献和注册报告,缺乏统一来源。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pregnant and lactating patients and their clinicians must navigate a fragmented therapeutic landscape when managing dermatoses that flare during pregnancy. Although a growing number of topical, systemic and procedural modalities, including newer biologics, small-molecule immunomodulators and narrow-band UVB, have demonstrated efficacy, safety and dosing data remain dispersed across disparate specialty literatures and registry reports. Reliance solely on US Food and Drug Administration (FDA) pregnancy categories and anecdotal experience fosters wide practice variation and therapeutic gaps. Effective therapies are often withheld, subtherapeutic regimens are prescribed and breastfeeding guidance is inconsistent. Furthermore, the exclusion of pregnant and lactating women from randomized trials leaves critical pharmacokinetic and teratogenicity questions unanswered. In part I of our CME we reviewed pregnancy and lactation induced immunologic, hormonal, vascular and barrier changes that exacerbate common dermatoses. In part II of this CME we present a consolidated, evidence-based framework regarding atopic dermatitis, psoriasis, acne vulgaris, rosacea, melasma, alopecia (due to telogen effluvium or androgenetic, hormonally and/or nutritionally related), and hidradenitis suppurativa that integrates up-to-date safety profiles, trimester-specific dosing adjustments, lactation pharmacology and clinical algorithms, all of which are essential to optimize maternal disease control while minimizing fetal and neonatal risk.
引用
- Lyons CE, Smith AD, Schwartzman G, et al. Managing Skin Diseases that Flare During Pregnancy and in the Postpartum period: Part 2- Management & Safety Considerations. J Am Acad Dermatol. 2026. PMID: 41692217. doi:10.1016/j.jaad.2026.01.090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。